单克隆抗体在结直肠癌治疗中的潜力
Fatemeh Heidari1, Soheil Madadi1, Neda Alizadeh2
1Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Shahid Fahmide Blvd, 6517838678, Hamadan, Iran.
Medical oncology (Northwood, London, England)
|August 21, 2023
概括
单克隆抗体 (mAbs) 为结直肠癌 (CRC) 治疗提供了一个有希望的,有针对性的方法,克服了传统化疗的局限性,并解决了瘤异质性,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药物开发 药物开发
背景情况:
- 大肠直肠癌 (CRC) 带来了重大治疗挑战,特别是转移性复发.
- 对CRC的传统化疗具有显著的局限性和副作用.
- 单克隆抗体 (mAbs) 正在成为冠状动脉癌的向治疗策略.
研究的目的:
- 审查应用单克隆抗体 (mAbs) 用于结直肠癌 (CRC) 治疗的进展情况.
- 讨论单独使用mAbs,组合使用或与小分子一起用于CRC治疗.
- 突出抗体工程如何克服瘤异质性等挑战.
主要方法:
- 对结直肠癌治疗中单克隆抗体研究的文献综述.
- 对抗体工程策略的当前研究进行分析.
- 讨论用于癌症治疗的双功能和三功能药物开发.
主要成果:
- 单克隆抗体证明了对CRC治疗的临床益处.
- mAbs提供了更有选择性的疗法,副作用和免疫性减少.
- 先进的抗体工程策略有助于克服瘤异质性.
结论:
- 单克隆抗体代表着结直肠癌治疗的重大进展.
- 应用mAbs,单独或组合,显示了改善治疗疗效的潜力.
- 未来的CRC疗法可能会利用工程抗体来对抗疾病的复杂性.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K